Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MRNA |
---|---|---|
09:32 ET | 78096 | 136.335 |
09:34 ET | 88458 | 134.985 |
09:36 ET | 28112 | 135.23 |
09:38 ET | 58185 | 133.6926 |
09:39 ET | 60431 | 134.13 |
09:41 ET | 21276 | 134.55 |
09:43 ET | 11661 | 134.74 |
09:45 ET | 57146 | 134.65 |
09:48 ET | 21720 | 134.08 |
09:50 ET | 17579 | 134.26 |
09:52 ET | 20390 | 134.03 |
09:54 ET | 9610 | 133.87 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Moderna Inc | 53.7B | -8.5x | --- |
ICON PLC | 25.9B | 38.5x | +4.68% |
Biogen Inc | 33.7B | 28.4x | -18.14% |
Biontech SE | 21.9B | 172.9x | --- |
Grifols SA | 6.0B | 23.7x | --- |
Incyte Corp | 13.9B | 19.4x | +39.11% |
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $52.8B |
---|---|
Revenue (TTM) | $5.2B |
Shares Outstanding | 383.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.68 |
EPS | $-15.66 |
Book Value | $36.27 |
P/E Ratio | -8.5x |
Price/Sales (TTM) | 10.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -99.73% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.